Get started
Author

Ayako Miyazawa

Observed names: A. Miyazawa, Miyazawa, Ayako
ORCID: 0000-0003-1108-8610
Observed ORCID: 0000-0003-1108-8610
OpenAlex ID: A5001909899
Regulation of PD-L1 expression by matrix stiffness in lung cancer cells
2017 · Ayako Miyazawa, Satoru Ito, et al. · Biochemical and Biophysical Research Communications · 118
PDF
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
2022 · Soei Gen, Ichidai Tanaka, et al. · BMC Cancer · 50
PDF
eIF 2β, a subunit of translation‐initiation factor EIF 2, is a potential therapeutic target for non‐small cell lung cancer
2018 · Ichidai Tanaka, Mitsuo Sato, et al. · Cancer Science · 34
PDF
Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non–Small-Cell Lung Cancer Patients With EGFR Mutation
2020 · Ichidai Tanaka, Masahiro Morise, et al. · Clinical Lung Cancer · 28
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
2018 · Ichidai Tanaka, Masahiro Morise, et al. · Lung Cancer · 28
UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer
2020 · Daiki Goto, Kazuki Komeda, et al. · Cancer Investigation · 10
Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients with EGFR -mutated non-small-cell lung cancer: a retrospective, multicenter cohort study
2024 · Ichidai Tanaka, Kazumi Hori, et al. · Therapeutic Advances in Medical Oncology · 3
Two Autopsy Cases of Lung Cancer Complicated with Pancreatic Tumors
2011 · Satoko Shimadu, Norio Yoshida, et al. · Haigan · 3
PDF
P1.03-13 eIF2β, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer
2018 · D. Goto, I. Tanaka, et al. · Journal of Thoracic Oncology · 2
P1.03-18 Mechanobiology of Lung Cancer Cells: Regulation of PD-L1 Expression by Matrix Stiffness
2018 · A. Miyazawa, S. Ito, et al. · Journal of Thoracic Oncology · 1
Survival advantage of postoperative recurrence compared to de novo stage IV disease in EGFR-mutant lung adenocarcinoma treated with osimertinib: a multicenter retrospective study
2026 · Mika Sato, Ichidai Tanaka, et al. · BMC Cancer
Stable Pleural Effusion as a Diagnostic Pitfall in Meigs Syndrome: A Case of a Benign Brenner Tumor with Elevated CA125
2026 · Tomonori Ito, Kazuma Sugiura, et al. · Internal Medicine
PDF
Diagnostic Challenge in Treatment-Emergent Neuroendocrine Prostate Cancer: A Case Requiring Prostate Rebiopsy After an Inconclusive Metastatic Lung Biopsy
2026 · Shiori Nakagaki, Tomonori Ito, et al. · Internal Medicine
PDF
P3.12.35 Real-World Clinical Outcomes of Osimertinib in Patients With Recurrent EGFR Mutated Lung Adenocarcinoma: A Multicenter Study
2025 · I. Tanaka, M. Sato, et al. · Journal of Thoracic Oncology
Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer: a retrospective, multicenter study
2024 · Ichidai Tanaka, Soei Gen, et al. · Research Square
PDF
Femoral bone metastasis is a poor prognostic factor in osimertinib-treated patients with EGFR-mutated non-small cell lung cancer
2023 · Ichidai Tanaka, Soei Gen, et al. · Research Square
PDF
Additional file 2 of Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
2022 · Gen, Soei, Tanaka, Ichidai, et al. · Figshare
UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer
2020 · Goto, Daiki, Komeda, Kazuki, et al. · Figshare
P2.03-23 UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer
2019 · D. Goto, M. Kizuki, et al. · Journal of Thoracic Oncology
PDF
An Autopsied Case of Hermansky-Pudlak Syndrome with Pulmonary Aspergillosis
2012 · Satoko Shimadu, Naoya Takeda, et al. · Nihon Naika Gakkai Zasshi
PDF
Works count: 22
Citation count: 277
H-index: 6
I10-index: 6
Year
Topic
Type